Cymabay Therapeutics, Inc. (NASDAQ: CBAY) is a clinical-stage biopharmaceutical company located in the San Francisco Bay Area focused on developing therapies to treat metabolic diseases with high unmet medical need or serious rare and orphan diseases. CymaBay was seeded with the assets from an earlier metabolic disease company in which more than $120M was invested to produce a robust pipeline. The company is committed to developing breakthrough medicines that improve the lives of patients and their families. For more information, visit the company’s website at www.cymabay.com.